Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought

2. Pacific Biosciences of California

Wood has several bets on the future of medical solutions. One investment she added to is Pacific Biosciences of California, or PacBio for short. It's a leader in long-read gene sequencing, arming scientists and clinical researchers with sequencing technologies to improve on current biology and health solutions.

PacBio also reported quarterly results last week, but it wasn't as impressive as the The Trade Desk's showing. Revenue rose a mere 2% to $40 million, short of analyst estimates. Its quarterly loss was in line with expectations.

Unlike The Trade Desk, shares of PacBio are trading sharply lower this year. However, the shares have more than doubled since bottoming out this summer. Analysts see revenue growth picking up next year and its losses narrowing significantly. It's still a couple of years away from achieving actual profitability, but it's taking steps in the right direction.

3. Guardant Health

Finally, there's Guardant Health, a developer of oncological tests. It also put out fresh financials late last week, and of the three reports it's the one the market liked the best. Shares of Guardant Health soared 13% on Thursday last week following its third-quarter numbers.

Revenue rose 34% to $191.5 million for the three months ending in September, blasting through the $170 million that analysts were modeling. Guardant Health also posted a much smaller loss than its shareholders were expecting. It also boosted its full-year guidance. With a balance sheet flush with cash and a promising pipeline of clinical or biopharmaceutical tests, Guardant Health has time to play out for its investors.

Don’t miss this second chance at a potentially lucrative opportunity

Ever feel like you missed the boat in buying the most successful stocks? Then you’ll want to hear this.

On rare occasions, our expert team of analysts issues a “Double Down” stock recommendation for companies that they think are about to pop. If you’re worried you’ve already missed your chance to invest, now is the best time to buy before it’s too late. And the numbers speak for themselves:

• Amazon: if you invested $1,000 when we doubled down in 2010, you’d have $23,295!*

• Apple: if you invested $1,000 when we doubled down in 2008, you’d have $42,465!*

• Netflix: if you invested $1,000 when we doubled down in 2004, you’d have $434,367!*

Right now, we’re issuing “Double Down” alerts for three incredible companies, and there may not be another chance like this anytime soon.

See 3 “Double Down” stocks »

*Stock Advisor returns as of November 11, 2024

Rick Munarriz has positions in The Trade Desk. The Motley Fool has positions in and recommends Guardant Health, Pacific Biosciences Of California, and The Trade Desk. The Motley Fool has a disclosure policy.

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought was originally published by The Motley Fool